{"title":"检查点抑制剂疗法：免疫相关不良事件管理。","authors":"Lori Davis, Mary Beth Casselbury, Sharon Wilson","doi":"10.1097/NSG.0000000000000083","DOIUrl":null,"url":null,"abstract":"<p><strong>Abstract: </strong>Treatment with immune checkpoint inhibitors for cancer is associated with a high prevalence of multiple immune-related toxicities. Immune-related adverse events (irAEs) can occur anytime during treatment and up to 3 months after treatment. This article discusses checkpoint inhibitor therapy and describes the implementation of a patient education program focused on recognizing immunotherapy irAEs and their toxicities.</p>","PeriodicalId":35641,"journal":{"name":"Nursing","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Checkpoint inhibitor therapy: Immune-related adverse event management.\",\"authors\":\"Lori Davis, Mary Beth Casselbury, Sharon Wilson\",\"doi\":\"10.1097/NSG.0000000000000083\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Abstract: </strong>Treatment with immune checkpoint inhibitors for cancer is associated with a high prevalence of multiple immune-related toxicities. Immune-related adverse events (irAEs) can occur anytime during treatment and up to 3 months after treatment. This article discusses checkpoint inhibitor therapy and describes the implementation of a patient education program focused on recognizing immunotherapy irAEs and their toxicities.</p>\",\"PeriodicalId\":35641,\"journal\":{\"name\":\"Nursing\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nursing\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1097/NSG.0000000000000083\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/10/18 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"Nursing\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nursing","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/NSG.0000000000000083","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/18 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"Nursing","Score":null,"Total":0}
Abstract: Treatment with immune checkpoint inhibitors for cancer is associated with a high prevalence of multiple immune-related toxicities. Immune-related adverse events (irAEs) can occur anytime during treatment and up to 3 months after treatment. This article discusses checkpoint inhibitor therapy and describes the implementation of a patient education program focused on recognizing immunotherapy irAEs and their toxicities.
期刊介绍：
Nursing2020 (ISSN 0360-4039; online ISSN 1538-8689) published its first issue in November 1971, under founders Gene W. Jackson and Daniel Cheney. In the intervening years, its circulation has grown to over 150,000, making it one of the largest nursing journals in the world. Published monthly, Nursing2020 is widely regarded as offering current, practical contents to its readers, and has won many editorial awards testifying to the quality of its copy and graphics. The editorial and clinical staff, a 19-member Editorial Board of distinguished clinicians and practitioners, and over 100 invited reviewers help ensure the quality of this publication.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
